DEF 14A: Prestige Consumer Healthcare Achieves Record Fiscal 2025 Results Amidst Challenging Environment

Prestige Consumer Healthcare Inc. reported record revenues, adjusted earnings per share, and strong free cash flow for fiscal year 2025, demonstrating consistent growth and strategic execution.

Summary

• Fiscal 2025 delivered record revenues of $1,138 million.
• Achieved record adjusted diluted EPS of $4.52, representing 7.3% growth.
• Generated strong free cash flow of approximately $243 million.
• Reduced debt to the lowest level in company history, achieving 2.4x leverage.
• Organic revenue growth for the fiscal year was 1.2%.
• The International OTC segment continued to show strong growth.
• The May 2022 performance stock unit grant resulted in an 80.5% payout for the three-year performance period (fiscal 2023-2025).

Sentiment

Score: 9

Explanation: The document reports record revenues, record adjusted EPS, strong free cash flow, and the lowest debt level in company history, all while navigating a challenging macroeconomic environment. This indicates exceptional performance and strong financial health.

Positives

• Record revenues of $1,138 million were achieved in fiscal 2025.
• Record adjusted diluted EPS of $4.52, marking a 7.3% increase from the previous year.
• Strong free cash flow generation of approximately $243 million.
• Debt was reduced to the lowest level in company history, with leverage at 2.4x.
• Maintained a long-term track record of consistent revenue and earnings growth.
• Achieved 1.2% organic revenue growth.
• Demonstrated continued strong growth in the International OTC segment.
• Received high stockholder approval (approximately 97%) for executive compensation at the 2024 Annual Meeting.
• Maintains robust corporate governance practices, including a majority of independent directors and annual director elections.

Negatives

• Operated within a 'challenging macroeconomic environment' and faced 'significant supply chain challenges' during fiscal 2025.
• A director, Sheila A. Hopkins, previously served as Interim Chief Executive Officer of Cutera, Inc., which filed Chapter 11 Bankruptcy in March 2025.

Risks

• Risks related to financial statements and the financial reporting process.
• Risks concerning accounting, legal, ethics, and compliance matters.
• Risks associated with information technology (IT) systems, artificial intelligence (AI), privacy, and cybersecurity management.
• Financial risks related to environmental, health, and safety matters.
• Risks concerning liquidity and capital allocation.
• Risks associated with the company's compensation philosophy and programs.
• Talent acquisition and retention risks.
• Human capital management and issues related to employment practices.
• Risks related to corporate governance, including adherence to Corporate Governance Guidelines.
• Corporate responsibility, sustainability, and environmental, health & safety related risks and opportunities.
• Economic, industry, enterprise, and operational risks inherent in the consumer products industry.
• Risks from cybersecurity threats.
• Risks related to supply chain disruptions and challenged suppliers.

Future Outlook

The company remains confident in its business attributes supporting a proven formula of solid organic growth, leading free cash flow generation, and a proven capital deployment strategy, expecting to deliver consistent and stable results even in a volatile business environment. The ongoing evolution of the business is anticipated to continue creating value for shareholders.

Management Comments

• "Fiscal 2025 delivered consistent revenue and earnings growth, continuing our long-term track record."
• "Record revenues, record adjusted earnings per share, and strong free cash flow growth were achieved thanks to our business strategy and the unique attributes of our portfolio."
• "Executing this strategy is an entire organization that continues to operate at the highest level of excellence thanks to our guiding principles of Leadership, Trust, Change, and Execution."
• "These business principles and traits have us well positioned to deliver consistent and stable results over time, even set against the backdrop of today's volatile business environment."
• "We remain confident in the big picture – that our business attributes support our proven formula of solid organic growth, leading free cash flow generation, and a proven capital deployment strategy."
• "We are excited about the ongoing evolution of our business and the ability to continue creating value for you, our shareholders."

Industry Context

Operating in the consumer health and personal care sector, the company highlights its ability to deliver consistent and stable results despite a 'volatile business environment' and 'significant supply chain challenges,' suggesting resilience compared to broader industry headwinds. Its focus on strong brands and high margins positions it favorably within the industry.

Comparison to Industry Standards

• The company's executive compensation targets approximate the median level of compensation offered by a peer group including companies such as Amphastar Pharmaceuticals, Church & Dwight Co., Energizer Holdings, Inc., Helen of Troy Limited, and The Hain Celestial Group, Inc.
• The company's Total Shareholder Return (TSR) for fiscal 2025 was $234.29 (based on an initial $100 investment in March 2020), which significantly outperformed the peer group's TSR of $164.93 for the same period.
• The company's Adjusted EBITDA for fiscal 2025 was $374.5 million, a key metric for comparison within its industry, indicating strong profitability.

Management Changes

Corporate Governance

Related Party Transactions

• No significant business relationships with related persons requiring disclosure under applicable SEC regulations since the beginning of fiscal 2025.
• No related party transactions are currently planned for fiscal 2026.
• The company has adopted a Related Persons Transaction Policy to govern such dealings, ensuring review and approval of transactions exceeding $120,000 if a related person has a direct or indirect material interest.

Stakeholder Impact

• Shareholders: Value creation through consistent revenue and earnings growth, strong free cash flow, debt reduction, and alignment of executive compensation with shareholder interests.
• Employees: Commitment to a safe work environment, fostering a strong company culture based on Leadership, Trust, Change, and Execution, and adherence to a strict Code of Conduct and Ethics.
• Consumers: Provision of trusted consumer healthcare brands, commitment to quality products, and integrity in manufacturing and marketing processes.
• Customers: Efforts to improve customer service levels despite supply chain challenges.
• Suppliers: Requirement to embrace and adhere to a Supplier Code of Conduct outlining environmental, ethical, and social responsibilities.
• Creditors: Significant debt paydown to the lowest level in company history, indicating improved financial stability and reduced risk.

Next Steps

• Elect seven directors nominated by the Board of Directors to serve until the 2026 Annual Meeting of Stockholders.
• Conduct an advisory vote to approve the compensation of named executive officers.
• Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
• Hold the 2025 Annual Meeting of Stockholders on August 5, 2025.
• The Board and its committees will conduct annual self-evaluations of their performance.
• The Nominating & Corporate Governance Committee will annually review the self-assessment process.
• Compensation Advisory Partners LLC (CAP) is expected to complete a full review of director compensation against the company's peer group in August 2025.
• The Board of Directors will review succession plans for senior leadership at least once annually.

Key Dates

Recommendation

Keywords

Consumer Healthcare, Personal Care, OTC Products, SEC Filing, Proxy Statement, Financial Performance, Earnings, Revenue Growth, Free Cash Flow, Debt Reduction, Corporate Governance, Executive Compensation, Risk Management, Supply Chain, Brand Building, Shareholder Value, NYSE, Prestige Consumer Healthcare